Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 13/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10776406 | 1.00 | CA1 (0.40) | CA1CA7CA12CA14CTSK | |
| SCHEMBL28556471 | 0.86 | CNR1 (0.44) | TDP1KMT2AMEN1 | |
| SCHEMBL12492444 | 0.86 | CNR1 (0.44) | TDP1KMT2AMEN1 | |
| SCHEMBL571467 | 0.85 | CTSK (0.40) | CA1CA7CA12CA14CTSK | |
| SCHEMBL20159624 | 0.85 | CTSK (0.40) | CA1CA7CA12CA14CTSK | |
| SCHEMBL16061377 | 0.85 | CTSK (0.40) | CA1CA7CA12CA14CTSK | |
| SCHEMBL6111877 | 0.82 | CTSK (0.40) | CA1CA7CA12CA14CTSK | |
| SCHEMBL7442687 | 0.82 | CA1 (0.40) | CA1CA7CA12CA14CTSK | |
| SCHEMBL7442690 | 0.82 | CA1 (0.40) | CA1CA7CA12CA14CTSK | |
| SCHEMBL166206 | 0.81 | CA1 (0.42) | CA1CA7CA12CA14CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097750-B2 | Highly enantioselective, converting aromatic and aliphatic aldehydes into optically active aryl and alkyl beta -amino acids | BRANDEIS UNIVERSITY (US) | 2012-01-17 | — | — | US | disclosed |
| US-20080228000-A1 | Cinchona Alkaloid-Catalyzed Asymmetric Mannich Reactions | BRANDEIS UNIVERSITY (US) | 2008-09-18 | — | — | US | disclosed |
| EP-0229944-A2 | Novel tetrahydroisoquinoline derivatives | SYNTEX (U.S.A.) INC. (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080228000-A1 | Cinchona Alkaloid-Catalyzed Asymmetric Mannich Reactions | MANBA, MAN2A1, ASNS | CA1 456/4885CA7 34/4885CA12 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.